Toward full financing of the ACT-Accelerator in 2021

MS COVID-19 Briefing

18 MARCH 2021

ACT now, ACT together to accelerate the end of the COVID-19 crisis
The Facilitation Council developed a Financing Framework which now anchors the ACT-Accelerator Strategy & Budget for 2021

**ACT-A funding gap for 2021 across value chain**
as of 11 March 2021

- Investments to ensure speed would need to be primarily HIC/UMIC-financed*: $1.7b
- R&D and Product Assessment
- Market Shaping & Manufacturing
- Procurement
- Demand Generation & In-Country Delivery

**Funding gap** (in USD billion)

- Investments to ensure equity of scarce products for LICs would need to be HIC/UMIC-financed: $13.1b
- Investments for common products available at fair prices could potentially be LIC-financed: $7.3b

Total: $22.1b

of which $0.2b yet to be allocated
ACT-Accelerator's contributions have reached US$ 11 billion so far

ACT-Accelerator funding, in US$ billion, as of 11 March 2021

Note: all financial commitments can be accessed at [https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker](https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker).

1. Excluding the new USG announcement of 11 March contributing US$ 3.5 billion to the Global Fund
2. Includes US$ 150 million from Gavi core resources, approved by the Board as catalytic funding for delivery of vaccines to AMC92 economies
3. Recent contributions to Global Fund are contingent on the allocation of these funds through the Global Fund’s C19RM process. Their allocation by Pillar is previsional
4. Several contributions to WHO are flexible. Their allocation by Pillar is previsional
5. US$ 470 million contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs
6. Pending allocation from contributors
ACT-Accelerator's generous contributors bring the funding gap to US$ 22.1 billion for 2021

**ACT-A contributors**\(^1\) as of 11 March 2021

**ACT-A funding gap for 2021, in US$ billion** as of 11 March 2021

---

Note: all financial commitments can be accessed at [https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker](https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker).

1. Excluding the new USG announcement of 11 March contributing US$ 3.5 billion to the Global Fund. US$ 11 billion include $470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs

2. Contributions <US$ 12m, and including $470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs
Political Momentum for the ACT-Accelerator and its Financing is Growing

Joint G7 Leaders’ Statement
February 19, 2021

We invite all partners, including the G20 and International Financial Institutions, to join us in increasing support to ACT-A.

European Council
February 26, 2021

We welcome COVAX’s first plans to distribute vaccines to 92 LMICs. We commit to contributing the EU’s fair share to the funding of ACT-A.

G20 Finance Ministers & Central Bank Governors’ Meeting
February 26, 2021

Granting equitable access to safe vaccines, diagnostics and therapeutics for all countries is a top priority for all the Ministers and Governors.
To build on this momentum, the Facilitation Council proposed a 5-step approach for countries to burden share the cost of ACT-A

5-step approach to build rational burden-sharing across HICs & UMICs, adjusted with qualitative analysis – modelled after IMF quota approach

Public, data driven analysis

| Contribution should be proportional to GDP | GDP adjusted to ‘openness’ per IMF quotas | Proportion rate on GDP/Capita used to reflect inequalities | Risk margin built in, in case non-contributing countries |

Confidential Ask

Final adjusted ask for each country using qualitative assessment1

---

1. For example, considering the debt or interest burden for UMICs
Model Outputs | Target contributions generated for each country, with a progressive contribution of GDP/Capita and 20% default risk buffer (1/2)

1. Model outputs including the 20% buffer to offset potential default risk of several targeted countries. Excluding EC.

**Model Outputs I** Target contributions generated for each country, with a progressive contribution of GDP/Capita and 20% default risk buffer (2/2)

Estimated contribution range by country¹, top 31-60 donors in USD Bn

The co-chairs Norway & South-Africa will adjust the **final ask** based on the target contribution from the model and other factors such as the debt situation.

1. Model outputs including the 20% buffer to offset potential default risk of several targeted countries. Excluding EC.
Norway and South Africa will soon engage in bilateral discussions with Heads of State to kick off the campaign.

**1. March 19th (tbc)**
- Letters sent to Heads of Government based on the *burden sharing* model

**2. March 23rd**
- Discussions between Norway, South Africa and contributing countries
- Follow up by Finance Working Group members

**3. April 7th**
- 2nd G20 Finance & Central Bank Governors Meeting

**Goal:** achieve initial financing announcements

**May 21st**
- Global Health Summit co-hosted by Italy & EC

The ACT-Accelerator Hub, hosted by WHO, will support the Co-Chairs outreach and Member State engagement along this process.
REMINDER: 5th ACT-A FACILITATION COUNCIL

PRE-BRIEF, 19 MARCH 12.30-14.00hr

AGENDA

1. Diagnostics & Therapeutics:
   state of play & looking forward

2. Look ahead to the 5th Council

Delegations can register HERE

5th COUNCIL, 23 MARCH 12.30-15.00hr

AGENDA

1. ACT-A diagnostics & therapeutics goals in 2021: what’s holding us back?
   Interactive panel discussion with countries & council members

2. Where do we have to focus to rapidly scale up supply to COVAX?
   Interactive panel discussion with CEPI, WHO, countries, CSOs & Council

Proceeding will be livestreamed for all Member States on the ACT Accelerator site
ACT now, ACT together to accelerate the end of the COVID-19 crisis